Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209507 · ClinicalTrials.gov registry record
Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 19
- Enrollment target
NCT01209507 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants.
The verdict
NCT01209507 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Gynecologic Oncology patients have several different chemotherapy regimens, and dexamethasone is now routinely given to prevent allergic reactions to the chemotherapeutic agents. The most common chemotherapeutic agents used are paclitaxel and carboplatin. This combination regimen is given every three weeks for a total of 5-6 doses. Each dose is given after administration of 20 mg dexamethasone twelve hours prior to and the morning of chemotherapy. Dexamethasone is used for its antiemetic effects, but also to minimize the potentially fatal hypersensitivity reaction that can occur with paclitaxel. Another commonly used chemotherapy regimens is weekly cisplatin given with one dose of dexamethasone for cervical cancer. Chronic steroids are known to cause adrenal suppression, but it is not known if the amount of dexamethasone given with the gynecologic cancer chemotherapy regimens described above causes adrenal insufficiency in these patients. The investigators hypothesis is that some women receiving steroids with their chemotherapy may have adrenal insufficiency, and that they will have greater than normal chemotherapy-related fatigue.
Interventions
- OTHER Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209507
The ClinicalTrials.gov registry entry for NCT01209507 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chemotherapy is the first listed.
NCT01209507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209507 about?
NCT01209507 is a clinical study titled "Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy". Gynecologic Oncology patients have several different chemotherapy regimens, and dexamethasone is now routinely given to prevent allergic reactions to the chemotherapeutic agents. The most common chemotherapeutic agents used are paclitaxel and carboplatin. This combination regimen is given every thre...
What is the current status of trial NCT01209507?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2010-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01209507?
The interventions under investigation include: Chemotherapy (OTHER).
Who is sponsoring clinical trial NCT01209507?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.